Breaking News: Impact Factor 2022 List Now Published
The highly anticipated Impact Factor 2022 list has been officially released, providing valuable insights into the significance of journals
Category: Pharma Updates
Read More
QS World University Rankings 2024 Released: MIT topped again
The highly anticipated QS World University Rankings for 2024 have been released, revealing the top universities worldwide. Once again, the Massachusetts Institute of Technology (MIT) has emerged as the leading institution, maintaining its position at the pinnacle of global higher education. MIT’s consistent excellence in research, innovation, and teaching has earned it the top spot…
Lupin & Maharashtra Government Join Forces to Tackle Cardiovascular Diseases & COPD
Collaboration to enhance healthcare services, ensure timely diagnosis, and improve accessibility of healthcare services
FDA Delays Decision on GSK’s $2 Billion Bone Cancer Medicine Acquisition
The FDA delays decision on GSK’s bone cancer medicine acquisition as it reviews new data provided by the pharmaceutical company.
Soliris Receives License for Refractory Generalised Myasthenia Gravis Treatment in China
Regulatory milestone marks third approval for Soliris in China, further expanding access to rare disease medicines
Expanded WHO Prequalified HPV Tests for Cervical Cancer Elimination Efforts
The World Health Organization (WHO) now includes a fourth HPV test in its approved list of assays. While most HPV infections resolve on their own, certain high-risk types can cause cervical cancer. Cervical cancer screening involves HPV testing.
A new clinical manual has been published to assist quality abortion care
The World Health Organization (WHO) released a manual for health workers, providing clinical advice on excellent abortion services and implementing consolidated guidance in 2022.
Eisai, Biogen’s Alzheimer’s medication, receives complete approval from an FDA panel
“Promising medication for Alzheimer’s, Leqembi, gains renewed support from experts. Clinical trial data confirms its efficacy, increasing the likelihood of FDA approval extension.”
Johnson & Johnson Announces the 2022 Health for Humanity Report, Showcasing Achievement of Objectives
Explore Johnson & Johnson’s 2022 Health for Humanity Report, revealing their ESG performance and progress towards the ambitious Health for Humanity 2025 Goals. Stay updated on their commitment to environmental, social, and governance responsibility.
China’s NMPA approves ILUMETRI (Tildrakizumab Injection) for moderate-to-severe plaque psoriasis treatment
Sun Pharma’s ILUMETRI (Tildrakizumab Injection) receives NMPA approval in China, expanding its market for the treatment of plaque psoriasis.
